We improved product growth margins to 95.1% driven by favorable sales mix. R&D expenses as a percentage of revenue declined, reflecting timing of spend on milestones in clinical trials. SG&A expense as a percentage of revenues was higher in the quarter due to ongoing launch expenses for POMALYST, pre-launch expenses for ABRAXANE in pancreatic cancer, incremental expenses for Inflammation and Immunology and expenses related to a large number of medical meetings in Q2 of this year. We expect SG&A as a percentage of revenue to trend lower over the remainder of the year. Our operating profit margin improved versus one year-ago and versus the prior quarter and reached 49.6% for the quarter. Our effective tax rate rose slightly in Q2 driven by higher sales for both POMALYST and ABRAXANE in the U.S. and their impact on geographic mix of income.